A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults

Trial Profile

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs V 160 (Primary) ; V 160 (Primary) ; Aluminium phosphate
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 21 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 22 Feb 2016 Planned End Date changed from 1 Apr 2016 to 1 Mar 2017, according to ClinicalTrials.gov record.
    • 25 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top